JP2012500815A - 抗ｃｄ５抗体 - Google Patents

抗ｃｄ５抗体 Download PDF

Info

Publication number
JP2012500815A
JP2012500815A JP2011524187A JP2011524187A JP2012500815A JP 2012500815 A JP2012500815 A JP 2012500815A JP 2011524187 A JP2011524187 A JP 2011524187A JP 2011524187 A JP2011524187 A JP 2011524187A JP 2012500815 A JP2012500815 A JP 2012500815A
Authority
JP
Japan
Prior art keywords
antibody
antibodies
composition according
antibody composition
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011524187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500815A5 (cg-RX-API-DMAC10.html
Inventor
ヨセフィネ・エル・コー・クリトゴー
チャールズ・パイク
ミッケル・ワンダール・ペダーセン
クラウス・ケーフェーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servier Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of JP2012500815A publication Critical patent/JP2012500815A/ja
Publication of JP2012500815A5 publication Critical patent/JP2012500815A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011524187A 2008-08-29 2009-08-28 抗ｃｄ５抗体 Withdrawn JP2012500815A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200801191 2008-08-29
DKPA200801191 2008-08-29
US9370008P 2008-09-02 2008-09-02
US61/093,700 2008-09-02
PCT/DK2009/050218 WO2010022737A1 (en) 2008-08-29 2009-08-28 Anti-cd5 antibodies

Publications (2)

Publication Number Publication Date
JP2012500815A true JP2012500815A (ja) 2012-01-12
JP2012500815A5 JP2012500815A5 (cg-RX-API-DMAC10.html) 2012-10-11

Family

ID=40677719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011524187A Withdrawn JP2012500815A (ja) 2008-08-29 2009-08-28 抗ｃｄ５抗体

Country Status (15)

Country Link
US (1) US20110250203A1 (cg-RX-API-DMAC10.html)
EP (1) EP2328932A1 (cg-RX-API-DMAC10.html)
JP (1) JP2012500815A (cg-RX-API-DMAC10.html)
KR (1) KR20110050541A (cg-RX-API-DMAC10.html)
CN (1) CN102137873A (cg-RX-API-DMAC10.html)
AU (1) AU2009287164A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0917148A2 (cg-RX-API-DMAC10.html)
CA (1) CA2735279A1 (cg-RX-API-DMAC10.html)
IL (1) IL209975A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011000970A (cg-RX-API-DMAC10.html)
NZ (1) NZ591153A (cg-RX-API-DMAC10.html)
RU (1) RU2011111640A (cg-RX-API-DMAC10.html)
TW (1) TW201011045A (cg-RX-API-DMAC10.html)
WO (1) WO2010022737A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201100300B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024028902A (ja) * 2018-04-18 2024-03-05 バイオマジソン・インコーポレイテッド ワクチン製剤の効力を特徴付けるための細胞バンク

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103490A2 (en) 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
US20140079722A1 (en) * 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
WO2013023162A2 (en) * 2011-08-10 2013-02-14 Genus Oncology, Llc Anti-muc1 antibodies for cancer diagnostics
MX350335B (es) 2011-08-17 2017-09-04 Univ California Anticuerpos que enlazan alfa-v beta-8 integrina.
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN102786595B (zh) * 2012-08-03 2014-04-23 无锡傲锐东源生物科技有限公司 抗cd5蛋白单克隆抗体及其用途
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
SG11201504920SA (en) * 2012-12-27 2015-07-30 Sanofi Sa Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
SG10201806481XA (en) * 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
HK1245171A1 (zh) 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
MA41962A (fr) 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
WO2017214285A1 (en) * 2016-06-07 2017-12-14 Eynav Klechevsky Detection of cd5 and methods and compositions for modulating cd5
RU2019102008A (ru) 2016-06-28 2020-07-28 Ксенкор, Инк. Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
SI4339615T1 (sl) * 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
AU2018374283B2 (en) 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
AU2019404302A1 (en) 2018-12-19 2021-08-05 The Trustees Of The University Of Pennsylvania Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
EP4149632A1 (en) 2020-05-14 2023-03-22 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
EP3915641A1 (en) * 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
JP2023538108A (ja) * 2020-08-21 2023-09-06 シティ・オブ・ホープ 抗ｃｄ５抗体組成物及びその使用
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
CN116801905A (zh) * 2020-12-17 2023-09-22 先声再明医药有限公司 Cd5抗体及其应用
WO2022152185A1 (zh) * 2021-01-12 2022-07-21 南京驯鹿医疗技术有限公司 靶向cd5的全人源抗体
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
EP4332118A1 (en) * 2021-04-29 2024-03-06 Korea Research Institute of Bioscience and Biotechnology Novel anti-cd5 chimeric antigen receptor and immune cell expressing same
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CN113105547B (zh) * 2021-05-18 2022-04-08 福州迈新生物技术开发有限公司 抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US12077597B2 (en) 2021-11-24 2024-09-03 International-Drug-Development-Biotech Anti-CD5 antibodies and methods of use thereof
US20230279080A1 (en) * 2021-12-27 2023-09-07 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
WO2024039683A1 (en) * 2022-08-15 2024-02-22 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024258967A1 (en) * 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025220805A1 (ko) * 2024-04-18 2025-10-23 주식회사 큐로셀 신규한 항-cd5 키메릭 항원 수용체 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312916C2 (de) * 1993-04-14 1995-03-23 Fresenius Ag Arzneimittel zur Behandlung von Immunreaktionen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024028902A (ja) * 2018-04-18 2024-03-05 バイオマジソン・インコーポレイテッド ワクチン製剤の効力を特徴付けるための細胞バンク
JP7853942B2 (ja) 2018-04-18 2026-04-30 バイオマジソン・インコーポレイテッド ワクチン製剤の効力を特徴付けるための細胞バンク

Also Published As

Publication number Publication date
BRPI0917148A2 (pt) 2015-12-01
KR20110050541A (ko) 2011-05-13
US20110250203A1 (en) 2011-10-13
RU2011111640A (ru) 2012-10-10
ZA201100300B (en) 2012-01-25
EP2328932A1 (en) 2011-06-08
CN102137873A (zh) 2011-07-27
AU2009287164A1 (en) 2010-03-04
WO2010022737A1 (en) 2010-03-04
CA2735279A1 (en) 2010-03-04
TW201011045A (en) 2010-03-16
IL209975A0 (en) 2011-02-28
NZ591153A (en) 2012-12-21
MX2011000970A (es) 2011-03-15

Similar Documents

Publication Publication Date Title
US20110250203A1 (en) Anti-cd5 antibodies
EP3380196B1 (en) Heterodimeric antibodies that bind cd3 and cd38
KR101805140B1 (ko) 재조합 항-표피 성장 인자 수용체 항체 조성물
CN112703013B (zh) Cd3抗原结合片段及其应用
CN113563470B (zh) 结合tigit抗原的抗体及其制备方法与应用
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
BR112019016204A2 (pt) anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
CN107365385A (zh) 抗cd38抗体
TW201141519A (en) Anti-HER2 antibodies and compositions
WO2015085847A1 (zh) Pd-1抗体、其抗原结合片段及其医药用途
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
EP4588524A2 (en) Anti-tigit and anti-pvrig in monotherapy and combination treatments
RU2770620C1 (ru) Связывающие молекулы, вызывающие клеточную активацию
KR20210114920A (ko) 인간 및 원숭이 cd38 항원에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
US20070136826A1 (en) Anti-mouse CD20 antibodies and uses thereof
KR102661163B1 (ko) 항 pd-1 항체 및 그의 용도
WO2021013061A1 (zh) 一种人源化抗vegfr2抗体及其应用
JP2023532248A (ja) 免疫関連疾患のためのｔｉｇｉｔに対するヒトモノクローナル抗体
EP3915641A1 (en) Anti-cd5 antibodies and methods of use thereof
KR20230145542A (ko) Tgf-베타-rii 결합 단백질
JP2023513059A (ja) 抗ミューラー管ホルモン受容体２抗体及び使用方法
AU2020257053B2 (en) Cell engaging binding molecules
CN116829590A (zh) Anti-pd-1抗体及其用途
US12077597B2 (en) Anti-CD5 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120827

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130729